A Study of Tetanus Antibody of Healthy Adults (tetanus)

July 20, 2026 updated by: Liu Si, Peking University First Hospital

A Prospective Study of Tetanus Antibody Protective Efficacy in Healthy Populations in Beijing

The goal of this observational study is to learn about antibody level of tetanus of adults in high-income city of china. The main question it aims to answer is:

  1. Analysis of tetanus antibody distribution across different age groups
  2. Evaluation of the TQS method for determining antibody status
  3. Correlation between primary vaccination history and tetanus antibody concentrations Blood samples were voluntarily provided by adult healthy participants for tetanus antibody analysis over a continuous collection period of more than one year.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

2009

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100034
        • Peking University First Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

This study will enroll healthy adults aged 18 years who reside in Beijing. Participants will be recruited voluntarily from the general population. Both males and females are eligible. Participants must be willing to provide a blood sample and complete a brief questionnaire regarding their vaccination history. Individuals with recent tetanus vaccination (within 5 years), acute illness, pregnancy, or immunosuppressive conditions will be excluded.

Description

Inclusion Criteria:

  • Voluntarily sign the informed consent form；
  • Be aged 18 years or older；
  • Be willing to provide a blood sample for biochemical testing

Exclusion Criteria:

  • Receipt of immunoglobulin, blood, or blood products within 6 months prior to enrollment；
  • Refusal to provide tetanus vaccination history (including vaccination records, CDC vaccine administration registry, or subject's recall)；
  • Individuals with recent tetanus vaccination (within 5 years), acute illness, pregnancy, or immunosuppressive conditions will be excluded

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
age group
20-29;30-39;40-49;50-59;≥60
gender group
male; female
education background
high school; bachelor; master; et al
primary vaccination
≥3 doses TTCV; < 3 doses TTCV; unknown
last TTCV dose duration
≤5 year;5-10 year; >10 year; unkown

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Tetanus Antibody Level
Time Frame: Baseline (single blood draw at enrollment)
Single blood draw
Baseline (single blood draw at enrollment)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
tetanus antibody level by TQS/mTQS method
Time Frame: Baseline (single blood draw at enrollment)
at baseline
Baseline (single blood draw at enrollment)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Peking University First Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 4, 2025

Primary Completion (Actual)

March 3, 2026

Study Completion (Actual)

May 15, 2026

Study Registration Dates

First Submitted

July 1, 2026

First Submitted That Met QC Criteria

July 20, 2026

First Posted (Actual)

July 24, 2026

Study Record Updates

Last Update Posted (Actual)

July 24, 2026

Last Update Submitted That Met QC Criteria

July 20, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2024R524
  • 2024IR10 (Other Grant/Funding Number: Peking University First Hospital)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Tetanus

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe